Advanced ovarian clear cell carcinoma with RAD50 mutation treated by PARP inhibitor pamiparib combined with anti-angiogenesis therapy: a case report. Issue 2 (15th November 2022)

• Record Type: Journal Article
• Authors: Huang, Xiaoyan; He, Xiaojian; Li, Dongliang; Chen, Xiong; Chen, Xi
• Is Part Of: Anti-cancer drugs. Volume 34:Issue 2(2023)
• Page Start: 290
• Page End: 293
• Publication Date: 2022-11-15
• Subjects: genetic testing -- ovarian clear cell carcinoma -- pamiparib -- RAD50 mutation -- targeted therapy; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000001412
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : Ovarian clear cell carcinoma (OCCC) is a relatively uncommon epithelial ovarian malignancy with unique clinical, histopathologic and genetic characteristics. Patients with advanced OCCC have poor outcomes and are resistant to standard chemotherapy. Targeted therapy offers a novel approach for treating OCCC. We report the case of a 45-year-old female patient with advanced OCCC who experienced relapse after standard treatment. Further, a frameshift mutation in the homologous recombination repair-related gene RAD50 (RAD50-p.I371Ffs*8) was identified by genetic testing. Next, the patient had received targeted combination therapy with poly (ADP-ribose) polymerase (PARP) inhibitor pamiparib and bevacizumab, achieving partial remission. Patient's symptoms improved significantly compared to before. To date, the patient has been followed up for more than half a year with favorable survival and high quality of life. The case report suggested that parmiparib-targeted therapy is a viable treatment option for advanced OCCC patients with RAD50 mutation.